GATA zinc finger domain containing 1 (GATAD1)

GATA zinc finger domain containing 1 (GATAD1) is a transcription factor characterized by a zinc finger domain at the N-terminus, enabling it to bind DNA and regulate gene expression via interaction with chromatin and histone modification sites[1][5]. It acts as an epigenetic regulator in diverse contexts: - In the heart, mutations in GATAD1 are causative for autosomal recessive dilated cardiomyopathy, likely through impaired histone binding and disruption of normal cardiac gene expression[1][3][4]. - In cancer, particularly glioma and hepatocellular carcinoma, GATAD1 gene amplification and overexpression promote malignancy: in glioma by directly upregulating CCND1 (Cyclin D1) transcription and promoting cell cycle progression, and in liver cancer by activating oncogenic pathways, marking GATAD1 as a prognostic indicator of disease severity[1][2]. - GATAD1 also plays a potential role in placental development, with altered expression linked to preeclamptic phenotypes[1]. - No drugs currently target GATAD1 directly, and it is not a current therapeutic target, but its role in disease makes it a prognostic and potentially diagnostic biomarker, especially in central nervous system and liver tumors[2]. GATAD1 is not associated with known major safety or therapeutic challenges. This target has no obvious naming or structural inconsistencies and is correctly classified as a nuclear transcription factor and chromatin regulator.

Other names

GATA zinc finger domain-containing protein 1ODAGocular development associated geneCMD2BRG083M05.2FLJ22489Ocular development-associated gene protein2310031E19Rik2810047M21Rik8430439A17RIK9130430G15RikB330017N08RIKzgc:136582